Autopsy report · NCT00418574
Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients
Cause of deathFutility
“No benefit on primary end point (RFS); no rationale to collect survival data”
Life of this trial
- Ran for about 4 years 6 months before it stopped.
- 888 participants enrolled.
- Results were posted on the registry 5 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2, Phase 3
- Sponsor
- Menarini Group
- Sponsor type
- Industry
- Conditions
- Ovarian Cancer
- Interventions
- Abagovomab; Placebo
- Participants
- 888
- Sites
- 150
- Countries
- Belgium, Czechia, France, Germany, Hungary, Italy, Poland, Spain, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.